KemPharm, Inc. (KMPH) |
|
5.81 -0.02 (-0.34%)
|
02-28 16:00 |
|
Open: |
5.83 |
Pre. Close: |
5.83 |
|
High:
|
5.97 |
Low:
|
5.79 |
|
Volume:
|
64,126 |
Market Cap:
|
200(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:02 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 6.19 One year: 7.09 |
| Support: |
Support1: 4.05 Support2: 3.36 |
| Resistance: |
Resistance1: 5.3 Resistance2: 6.07 |
| Pivot: |
4.88  |
| Moving Average: |
MA(5): 4.65  MA(20): 5.05
MA(100): 5.06 MA(250): 5.13 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 32.1 %D(3): 30 |
| RSI: |
RSI(14): 46 |
| 52-week: |
High: 6.92 Low: 4 |
| Average Vol(K): |
3-Month: 227 (K) 10-Days: 378 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KMPH ] has closed above bottom band by 46.3%. Bollinger Bands are 108.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.02 - 5.04 |
5.04 - 5.05 |
|
Low:
|
4.65 - 4.67 |
4.67 - 4.69 |
|
Close:
|
4.77 - 4.8 |
4.8 - 4.83 |
|
Company Description |
|
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida. |
Headline News |
Tue, 28 Feb 2023
Ergoteles LLC Has $761000 Stock Holdings in KemPharm, Inc ... - MarketBeat
Mon, 27 Feb 2023
KemPharm (KMPH) Files Preliminary Proxy - StreetInsider.com
Wed, 22 Feb 2023
KemPharm Announces Corporate Name Change to Zevra Therapeutics - Yahoo Finance
Tue, 31 Jan 2023
KemPharm Enhances Senior Management Team - GlobeNewswire
Tue, 24 Jan 2023
KemPharm Issues Letter to Shareholders - GlobeNewswire
Thu, 12 Jan 2023
KemPharm, Inc. (NASDAQ:KMPH): Are Analysts Optimistic? - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
35 (M) |
| Shares Float |
31 (M) |
|
% Held by Insiders
|
10.2 (%) |
|
% Held by Institutions
|
19.7 (%) |
|
Shares Short
|
1,370 (K) |
|
Shares Short P.Month
|
1,550 (K) |
Stock Financials |
|
EPS
|
-3.21 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-14.65 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-172 |
|
Return on Assets (ttm)
|
-9 |
|
Return on Equity (ttm)
|
-31.3 |
|
Qtrly Rev. Growth
|
46.2 |
|
Gross Profit (p.s.)
|
0.77 |
|
Sales Per Share
|
0.31 |
|
EBITDA (p.s.)
|
-0.52 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-15 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-1.5 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.33 |
|
Price to Sales
|
15.44 |
|
Price to Cash Flow
|
-10.97 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-12-27 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
